ISSN (Online) : 2277-4572
Author(s): Preetha Selva*, Saranya M
Aprepitant is a recently introduced NK1 receptor antagonist. It effectively blocks Substance- P, which is supposed to have emetic action. Hence, this newer drug is being used in patients undergoing chemotherapy to prevent chemotherapy induced nausea and vomiting (CINV). This particular review article gives a bird’s eye view on aprepitant, which is being tried as an adjuvant anti emetic in patients with far advanced cancer.
